Hanne Mariën
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hanne Mariën has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Elien Derveaux
Hasselt University, Institute for Materials Research (IUMAT), Metabolomics and Advanced Solid State NMR Group (MAS-NMR), Martelarenlaan 42, B-3500 Hasselt, Belgium
2 shared publications - Karolien Vanhove
Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, B-3500 Hasselt, Belgium
2 shared publications - Liesbet Mesotten
Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, B-3500 Hasselt, Belgium
2 shared publications - Michiel Thomeer
University of Hasselt, Ziekenhuis Oost-Limburg, Hasselt, Genk, Belgium
2 shared publications - Peter Adriaensens
Hasselt University
2 shared publications Byron Olson
1 shared publication
Latest Publications
- Open Access
- 14 June 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (6) , 545
Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review
Lung cancer is the leading cause of cancer-related mortality worldwide, with five-year survival rates varying from 3–62%. Screening aims at early detection, but half of the patients are diagnosed in advanced stages, limiting therapeutic possibilities. Positron emission tomography-computed tomography (PET-CT) is an essential technique in lung cancer detection and staging, with a sensitivity reaching 96%. However, since elevated 18F-fluorodeoxyglucose (18F-FDG) uptake is not cancer-specific, PET-CT often fails to discriminate between malignant and non-malignant PET-positive hypermetabolic lesions, with a specificity of only 23%. Furthermore, discrimination between lung cancer types is still impossible without invasive procedures. High mortality and morbidity, low survival rates, and difficulties in early detection, staging, and typing of lung cancer motivate the search for biomarkers to improve the diagnostic process and life expectancy. Metabolomics has emerged as a valuable technique for these pitfalls. Over 150 metabolites have been associated with lung cancer, and several are consistent in their findings of alterations in specific metabolite concentrations. However, there is still more variability than consistency due to the lack of standardized patient cohorts and measurement protocols. This review summarizes the identified metabolic biomarkers for early diagnosis, staging, and typing and reinforces the need for biomarkers to predict disease progression and survival and to support treatment follow-up.
- 14 June 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (6) , 545
Open AccessChanges in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review
Lung cancer is the leading cause of cancer-related mortality worldwide, with five-year survival rates varying from 3–62%. Screening aims at early detection, but half of the patients are diagnosed in advanced stages, limiting therapeutic possibilities. Positron emission tomography-computed tomography (PET-CT) is an essential technique in lung cancer detection and staging, with a sensitivity reaching 96%. However, since elevated 18F-fluorodeoxyglucose (18F-FDG) uptake is not cancer-specific, PET-CT often fails to discriminate between malignant and non-malignant PET-positive hypermetabolic lesions, with a specificity of only 23%. Furthermore, discrimination between lung cancer types is still impossible without invasive procedures. High mortality and morbidity, low survival rates, and difficulties in early detection, staging, and typing of lung cancer motivate the search for biomarkers to improve the diagnostic process and life expectancy. Metabolomics has emerged as a valuable technique for these pitfalls. Over 150 metabolites have been associated with lung cancer, and several are consistent in their findings of alterations in specific metabolite concentrations. However, there is still more variability than consistency due to the lack of standardized patient cohorts and measurement protocols. This review summarizes the identified metabolic biomarkers for early diagnosis, staging, and typing and reinforces the need for biomarkers to predict disease progression and survival and to support treatment follow-up.
- Open Access
- 17 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5602
Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics
Lung cancer cells are well documented to rewire their metabolism and energy production networks to enable proliferation and survival in a nutrient-poor and hypoxic environment. Although metabolite profiling of blood plasma and tissue is still emerging in omics approaches, several techniques have shown potential in cancer diagnosis. In this paper, the authors describe the alterations in the metabolic phenotype of lung cancer patients. In addition, we focus on the metabolic cooperation between tumor cells and healthy tissue. Furthermore, the authors discuss how metabolomics could improve the management of lung cancer patients.
- 17 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5602
Open AccessUnraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics
Lung cancer cells are well documented to rewire their metabolism and energy production networks to enable proliferation and survival in a nutrient-poor and hypoxic environment. Although metabolite profiling of blood plasma and tissue is still emerging in omics approaches, several techniques have shown potential in cancer diagnosis. In this paper, the authors describe the alterations in the metabolic phenotype of lung cancer patients. In addition, we focus on the metabolic cooperation between tumor cells and healthy tissue. Furthermore, the authors discuss how metabolomics could improve the management of lung cancer patients.
- Open Access
- 1 January 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 226 (1) , S656-S657
Validation of a new electrophysiological fetal heart rate monitor: comparison with cardiotocography
- 1 January 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 226 (1) , S656-S657
Open AccessValidation of a new electrophysiological fetal heart rate monitor: comparison with cardiotocography